Literature DB >> 11414745

Cytokine and chemokine dysregulation in hyper-IgE syndrome.

J Chehimi1, M Elder, J Greene, L Noroski, E R Stiehm, J A Winkelstein, K E Sullivan.   

Abstract

Hyper-IgE syndrome is characterized by severe recurrent staphylococcal infections, eczema, bone abnormalities, and markedly elevated levels of immunoglobulin E (IgE). The genetic basis is not known and the central immunologic defect is largely undefined. Reduced neutrophil chemotaxis is often described, and variable T cell defects have been demonstrated in some patients. It has been hypothesized that hyper-IgE is associated with a Th1/Th2 imbalance. We wished to characterize cytokine and chemokine imbalances that might reflect the underlying disease process or reflect ongoing pathologic processes. Nine patients with hyper-IgE syndrome and six controls were studied. Radioimmunoassays, flow cytometry, and gene array analyses were performed to characterize cytokine and chemokine production. Hyper-IgE patients express more IL-12, while ENA-78, MCP-3, and eotaxin are markedly underexpressed. Underexpression of a set of chemokines could explain a number of features of hyper-IgE syndrome and may offer a new paradigm for the understanding of this disorder. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414745     DOI: 10.1006/clim.2001.5039

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

Review 1.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

2.  Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome.

Authors:  Natalia I Dmitrieva; Avram D Walts; Dai Phuong Nguyen; Alex Grubb; Xue Zhang; Xujing Wang; Xianfeng Ping; Hui Jin; Zhen Yu; Zu-Xi Yu; Dan Yang; Robin Schwartzbeck; Clifton L Dalgard; Beth A Kozel; Mark D Levin; Russell H Knutsen; Delong Liu; Joshua D Milner; Diego B López; Michael P O'Connell; Chyi-Chia Richard Lee; Ian A Myles; Amy P Hsu; Alexandra F Freeman; Steven M Holland; Guibin Chen; Manfred Boehm
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome.

Authors:  E D Renner; I Pawlita; F Hoffmann; V Hornung; D Hartl; M Albert; A Jansson; S Endres; G Hartmann; B H Belohradsky; S Rothenfusser
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

4.  Distinct gene expression patterns of peripheral blood cells in hyper-IgE syndrome.

Authors:  T Tanaka; H Takada; A Nomura; S Ohga; R Shibata; T Hara
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

Review 5.  Infections in patients with inherited defects in phagocytic function.

Authors:  Timothy Andrews; Kathleen E Sullivan
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis.

Authors:  Desa Lilic; Ian Gravenor; Neil Robson; David A Lammas; Pam Drysdale; Jane E Calvert; Andrew J Cant; Mario Abinun
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

7.  Genetic origins of hyper-IgE syndrome.

Authors:  Yoshiyuki Minegishi; Hajime Karasuyama
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

Review 8.  The hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

9.  Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Chia-Lang Nhan-Chang; Neil Hamill; Edi Vaisbuch; Tinnakorn Chaiworapongsa; Samuel S Edwin; Jyh Kae Nien; Ricardo Gomez; Jimmy Espinoza; Claire Kendal-Wright; Sonia S Hassan; Gillian Bryant-Greenwood
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

10.  Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.

Authors:  Ellen D Renner; Stacey Rylaarsdam; Stephanie Anover-Sombke; Anita L Rack; Janine Reichenbach; John C Carey; Qili Zhu; Annette F Jansson; Julia Barboza; Lena F Schimke; Mark F Leppert; Melissa M Getz; Reinhard A Seger; Harry R Hill; Bernd H Belohradsky; Troy R Torgerson; Hans D Ochs
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.